Barclays Reiterates Rating on Cencora, Inc. $COR

Key Points

  • Barclays now rates Cencora, Inc. ($COR) "buy" with a $350.00 target.
  • The Street's average $COR price target is $350.58 (Buy).
  • $COR last traded around $281.67.

Barclays reiterated its rating on Cencora, Inc. ($COR) to a "buy" rating, with a price target of $350.00 in a recent research note.

Cencora, Inc. ($COR) Stock

Last price$281.67
Market cap$54.80B
P/E ratio21.60
Forward P/E14.24
PEG ratio0.60
Beta0.59
52-week low$244.82
52-week high$377.54
50-day MA$289.38
200-day MA$325.12
Current ratio0.95
Quick ratio0.48
Debt-to-equity4.21

Cencora, Inc. Earnings

EPS (ttm)$13.04
Revenue (ttm)$328.68B
Revenue growth3.8%
Net margin0.8%
Return on equity107.1%
Next earningsAug 5, 2026

Cencora, Inc. Dividend

Annual dividend$2.40
Dividend yield85.00%
Payout ratio17.6%
Ex-dividend dateMay 15, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$350.58
High target$412.00
Low target$280.00
Analysts covering12

About Cencora, Inc.

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

ExchangeNYSE
SectorHealthcare
IndustryMedical Distribution
HeadquartersConshohocken, PA
CEODr. Robert P. Mauch Ph.D., PharmD
Employees47,000

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.